Please activate JavaScript!
Please install Adobe Flash Player, click here for download

kontinenz aktuell - Ausgabe 01-2014

kontinenz aktuell März/201414 Interessenskonflikt: Der korrespondierende Autor gibt an, dass kein Interessenskonflikt besteht. Korrespondenzanschrift: Dr. Dag Schütz Chefarzt Klinik für Geriatrie Evangelisches Krankenhaus Essen-Werden gGmbH Pattbergstraße 1–3 45239 Essen E-Mail: d.schuetz@kliniken-essen-su- ed.de Reference List (1)Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol Suppl 1988;114:5–19. (2) Blazer DG, Federspiel CF, Ray WA, Schaffner W. The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontol 1983 January;38(1):31–5. (3) Brown, J.S.: Epidemiology and diagnosis of OAB. Geriatrics. Supp 10, Targeting optimal care for patients with OAB, 2004, 2 – 5 (4) Charach, G., Greenstein, A., Rabinovich, P., et. al.: Alleviating constipation in the elderly improves lower urinery tract symptoms. Gerontology 47, 2001, 72 – 76 (5) Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA et al. A model of anti- cholinergic activity of atypical antipsychotic medi- cations. Schizophr Res 2006 December; 88 (1–3):63–72. (6) Chung, J.M., Lee, S.D., Kang, D.I., et. al.: Preva- lence and associated factors of overactive bladder in Korean children 5–13 years old: a nationwide multicenter study. Urology 73, 2009, 63–67 (7) Coyne, K.S., Brooks, C., Koop, Z., et. al.: The prevalence of chronic constipation and faecal in- continence among men and women with symptoms of overactive bladder. BJU Int. 107 (2), 2011, 254 – 261 (8) Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003 November;48(2):133–43. (9) Dusing R. [Strategies to improve adherence with antihypertensive treatment]. Dtsch Med Wo- chenschr 2007 November;132(46):2455–7. (10) Füsgen, I.: Die überaktive Blase im Alter. In: Überaktive Blase (ÜAB)-aktuell. U. Jonas (Hrsg.). Thieme, Stuttgart, 2005, 27 – 33 (11) Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in ol- der adults: results of a US consensus panel of ex- perts. Arch Intern Med 2003 December 8;163 (22):2716–24. (12) Griffith, D., Derbyshire, S., Stenger, A., et. al.: Brain Control of normal and overactive bladder. J. Urol., 2005, 1862 – 1867 (13) Hanke F. Arzneimittelbezogene Probleme bei 127 Heimbewohnern. 2007 Jan 1. Report No.: Ba- sic Clin Pharmacol Tox 101. (14) Haruta, H. Sakakibara, R., Ogata, T., et. al.: Inhibitory control task is decresased in vaskular in- continence patients. Clin Anton Res 23(2), 2013, 85–89 (15) Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG et al. A drug burden index to define the functional burden of medications in ol- der people. Arch Intern Med 2007 April 23; 167(8): 781–7. (16) Hsiao SM, Lin HH, Kuo HC. International pro- state symptom score for assessing lower urinary tract dysfunction in women. Int Urogynecol J 2012 May 16. (17) Jonas, U.: Definition, Symptomatologie, Ätiolo- gie und Prävalenz. In: Überaktive Blase (ÜAB)-aktu- ell. U. Jonas (Hrsg.). Thieme, Stuttgart, 2005, 1–8 (18) Liao, Y.M., Dougherty, M.C., Beamer, P.P., et. al.: Factors related to lower urinary tract symptoms among a sample of employed women in Taipei. Neurourol Urodyn 27, 2008, 52–59 (19) Madersbacher, H., Averbeck, M.: Obstipation und LUTS – Wie beeinflussen sie sich gegenseitig? Referateband 23. Kongress der Deutschen Konti- nenzgesellschaft, Köln 2011, 63–64 (20) Milson, I., Abrams, P., Cardozo, L., et. al.: How widespread are the symptoms of on overactive bladder and how are they managud? BJU Int. 87 (9), 2001, 760–766 (21) Müller, St. C.: Interstitielle Zystitis bleibt oft un- erkannt. Nach Dtsch. Ärztebl. 109 (37), 2012, 1434 (22) Peron, E.P., Zheng, Y., Perera, S., et. al.: Anti- hypertensive drug class use and differential risk of community-dwelling older women. J Gerontol A Biol Sci Med Sci 67(12), 2012, 1373–1378 (23) Primus, G.: Dranginkontinenz im Alter. Ärzte- krone 13, 2013, 20 (24) Reitz, A.: Die überaktive Blase. Hausarztpraxis 10–11, 2012, 36–38 (25) Rodrigues P, Meller A, Campagnari JC, Alcan- tara D, D’Imperio M. International Prostate Symp- tom Score--IPSS-AUA as discriminat scale in 400 male patients with lower urinary tract symptoms (LUTS). Int Braz J Urol 2004 March;30(2):135–41. (26) Rudolph JL, Salow MJ, Angelini MC, McGlin- chey RE. The anticholinergic risk scale and anticho- linergic adverse effects in older persons. Arch Intern Med 2008 March 10;168(5):508–13. (27) Rosso, A.L., Eaton, C.B., Wallace, R., et. al.: Geriatic syndroms and incident disability in older women: results from the women’s health initiative observational study. JAGS 61(3), 2013, 371–379 (28) Schultz-Lampel, D.: Diagnostik der überaktiven Blase. In: Überaktive Blase (ÜAB)-aktuell. U. Jonas (Hrsg.). Thieme, Stuttgart 2005, 17 – 26 (29) Wehrberger, C., Madersbacher, S., Jungwirth, S. et. al.: lower urinary tract symptoms and urinary incontinence in a geriatric cohort – apopulation – based analysis. (30) Zhu, L., Lang, J., Liu, C., et. al.: The epidermio- logical study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause 16, 2009, 831 Übersichtsarbeit

Seitenübersicht